Chrysea is a synthetic biology company, developing  healthy-lifespan and precision nutritional interventions supported by rigorous clinical research, aimed at ameliorating a natural occurring anti-ageing mechanism called autophagy – a process on how cells recycle and get rid of damaged structures, which is critical for maintaining cell-health, renewal, and survival as well as to promote general health-span and manage the impact of age-related diseases.

Sector: Synthetic Biology


200M Fund Amount: 3.721.387,04 €
Co-investors: JuvLife (Juvenescence Group)
Stage: Venture Round
Region: Central Region
Investment Date: september 2021